# CHICKEN SOUP FOR THE BUSY COORDINATOR

## **SEP 2020**

# Remote Source Document Verification (SDV) Requirements

### Case scenario

Sponsor A had to postpone on-site monitoring visits due to visit restrictions imposed by the trial site arising from the COVID-19 situation. As an interim database lock was soon approaching, sponsor A decided to conduct remote monitoring visits instead to verify the data that had been transcribed from the source documents to the case report forms (CRFs). Thus, monitor B requested for the Clinical Research Coordinator (CRC) to share the source documents for the required trial participants remotely via a video call.

What should the CRC do to prepare for the remote SDV?

## **Checklist for remote SDV**

<ul> <li>✓ Ensure that the sponsor has obtained written agreement from the trial site for remote SDV.</li> <li>✓ The written agreement may be in the form of an addendum to the clinical trial agreement or via email.</li> </ul>
<ul> <li>✓ Check that the sponsor has notified the Health Sciences Authority (HSA) about the remote SDV plans prior to implementation.</li> <li>✓ The notification may be submitted to HSA at HSA CT@hsa.gov.sg.</li> <li>✓ File a copy of the notification in the Investigator Site Files.</li> </ul>
<ul> <li>✓ Ensure that the required source documents have been redacted by replacing the identifiable information (e.g. name, address, contact details etc.) with the trial participant ID.</li> <li>✓ Retain copies of the redacted source documents on file for documentation purposes.</li> </ul>
<ul> <li>✓ Request another study staff to verify that all identifiable information has been removed from the redacted source documents prior to the remote SDV.</li> <li>✓ The verification should be documented and maintained on file.</li> </ul>
✓ Ensure that the redacted source documents are shared via the video call in a secured manner (e.g. disable screen recording and prohibit screen shots).

#### Reference:

Guidance on Conduct of Clinical Trials in relation to the COVID-19 situation – version dated 29 Jul 2020

#### **Additional Reading Material:**

2. NHG Proper Conduct of Research SOP: 501-B07 Study Conduct - Monitoring

Article Contributed By: Ms. Sumitra Sachidanandan, Regulatory Consultant, Health Sciences Authority Edited By: NHG Group Research, OHRPP

\*Disclaimer: All characters appearing in this article are fictitious. Any resemblance to real persons is purely coincidental.

Best practices may differ between institutions. Readers are encouraged to follow their institution's policies/guidelines relating to the above scenarios/case study.